for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Richter Gedeon Vegyeszeti Gyar Nyrt

GDRB.BU

Latest Trade

8,435.00HUF

Change

25.00(+0.30%)

Volume

205,803

Today's Range

8,395.00

 - 

8,495.00

52 Week Range

6,280.00

 - 

9,320.00

As of on the Budapest Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
8,410.00
Open
8,420.00
Volume
205,803
3M AVG Volume
4.23
Today's High
8,495.00
Today's Low
8,395.00
52 Week High
9,320.00
52 Week Low
6,280.00
Shares Out (MIL)
186.11
Market Cap (MIL)
1,598,164.00
Forward P/E
14.33
Dividend (Yield %)
2.63

Next Event

Q3 2021 Richter Gedeon Vegyeszeti Gyar Nyrt Earnings Release

Latest Developments

More

Hungary Richter's CEO affirms revenue guidance, sees rising marketing spending in H2

Hungary's Richter posts HUF 28 bln Q2 net profit, exceeding forecasts

Hungary's Richter gets EU approval for uterine fibroid medicine

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Richter Gedeon Vegyeszeti Gyar Nyrt

Richter Gedeon Vegyeszeti Gyar Nyrt is a Hungary-based company engaged in the research, development, production and marketing and trade of pharmaceutical products. The Company’s business is structured into three segments: the Pharmaceuticals segment, which includes the companies that are involved in the Company’s core business, including research, development and production of pharmaceutical products; the Wholesale and retail segment covers distribution companies and pharmacies that are part of the sales network in various regional markets and, as such convey its products to consumers, and the Other segment presents all the other consolidated companies that provide marketing and sales support services. The Company’s subsidiaries include, among others, Gedeon Richter Romania SA, Gedeon Richter Polska Sp Z.o.o., and ZAO Gedeon Richter-RUS.

Industry

Biotechnology & Drugs

Contact Info

Gyomroi ut 19-21.

1103

Hungary

+36.1.4314027

https://www.richter.hu/

Executive Leadership

Erik Bogsch

Chairman of the Board of Directors, Member of the Executive Board

Attila Laszlo Chikan

Independent Chairman of the Supervisory Board

William de Gelsey

Honorary Chairman

Gabor Orban

Chief Executive Officer, Member of the Executive Board, Member of the Board of Directors

Gabor Gulacsi

Chief Financial Officer, Member of the Executive Board, Member of the Board of Directors

Key Stats

2.00 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, HUF)

2018

445.5K

2019

507.8K

2020

566.8K

2021(E)

600.9K
EPS (HUF)

2018

298.590

2019

467.731

2020

563.000

2021(E)

613.963
Price To Earnings (TTM)
16.09
Price To Sales (TTM)
2.73
Price To Book (MRQ)
1.95
Price To Cash Flow (TTM)
11.20
Total Debt To Equity (MRQ)
3.02
LT Debt To Equity (MRQ)
1.33
Return on Investment (TTM)
11.76
Return on Equity (TTM)
10.31

Latest News

Latest News

CEE MARKETS-Budapest, Prague stocks hit record highs on recovery hopes

Central European stocks extended their advance on Wednesday, with indexes in Budapest and Prague scaling fresh highs as they tracked a rise in global markets, while better than expected corporate earnings also boosted the region's bourses. Equities in Europe and the United...

CEE MARKETS-FX stabilises, worries over Delta variant persist

Central European currencies held stable on Tuesday after losses in the previous session, as traders and analysts expected worries about the Delta variant's spread to keep pressuring markets in the region. The Hungarian forint edged up 0.09%, trading at 359.50 per euro —...

Orban extends dominance through Hungarian university reform

Hungary's parliament passed legislation on Tuesday setting up foundations to take over the running of universities and cultural institutions in a move critics say extends the ideological imprint of the ruling right-wing government.

Orban seen entrenching right-wing dominance through Hungarian university reform

Hungary is set to pass legislation on Tuesday setting up foundations to take over the running of universities and cultural institutions in a move critics say extends the ideological imprint of the ruling right-wing government.

CEE MARKETS-FX virtually unchanged, Budapest stocks outperform

Central European currencies were mixed in thin trading on Tuesday and regional stocks retreated from highs in the previous session, with Budapest outperforming the region, helped by leading pharmaceutical company Richter Gedeon. On Monday, Prague's main share index tested...

CEE MARKETS-Currencies nearly flat ahead of Polish cenbank rate decision

Central European currencies were little changed on Wednesday, ahead of the Polish central bank's monetary policy meeting outcome, where analysts expect it to keep rates on hold, although some see a chance for another rate cut this year. The zloty was little changed, edging...

CEE MARKETS-Currencies, stocks mixed as EU budget veto dominates market mood

The Hungarian forint and the Polish zloty recouped some of their losses from the previous session on Thursday as markets in the CEE region were eyeing developments in the row over the European Union's budget and recovery fund, analysts said. Poland and Hungary are blocking...

Orban proposes change to Hungary's election law, opposition cries foul

Hungary's government submitted draft bills late on Tuesday which could force opposition parties to link up to fight an election and reduces transparency over public money, prompting a withering rebuke from the opposition.

Hungary's Richter has manufactured Remdesivir for 3,000 COVID-19 patients

Hungarian drugmaker Richter has manufactured enough doses of COVID-19 drug Remdesivir to treat 3,000 patients, spokeswoman Zsuzsa Beke said on Wednesday, amid shortages of the medication in Europe.

MEDIA-Richter's new uterine fibroid drug could sell EUR 80 mln/yr - MTI cites Vilaggazdasag

A Richter Gedeon Vegyeszeti Gyar Nyrt. statement for the daily Vilaggazdasag was quoted by national news agency MTI as follows:

Hungary's Richter could become takeover target after state stake transfer - chairman

A bill submitted by the Hungarian government to transfer state-owned shares in drugmaker Gedeon Richter to an education foundation could open the door to a takeover of the group, its chairman told website Portfolio.hu on Tuesday.

EUROPE RESEARCH ROUNDUP-Carnival, Idorsia Ltd, Weir Group

Securities analysts revised their ratings and price targets on several European companies, including Idorsia Ltd, Next and Richter, on Monday. HIGHLIGHTS * Carnival : HSBC raises to buy from hold; cuts target price to 1280p from 3500p * Idorsia Ltd : Credit Suisse raises...

CEE MARKETS-Forint and stocks gain, Richter shares outperform on Q1 earnings

The Hungarian forint firmed, outperforming its regional peers, while Central European stock markets strengthened on Friday, helped by a global risk-on mood on hopes that trade tensions between the United States and China were easing. The forint gained 0.25% and was trading...

Hungarian drugmaker Richter raises margin guidance after profit jump

Hungarian drugmaker Richter <GDRB.BU> posted a close to 32% jump in first-quarter net profit on Friday and raised its operating profit margin guidance on favourable exchange rates and coronavirus-related cost reductions.

BRIEF-Hungary's Richter raises 2020 operating margin guidance -CEO

* DEMAND-SIDE IMPACTS OF CORONAVIRUS PANDEMIC SIGNAL DECLINE IN TURNOVER FOR SOME PRODUCTS -CEO

BRIEF-Hungary's Richter Q1 net profit HUF 29 bln, above forecast

* Q1 NET PROFIT HUF 29 BILLION VERSUS HUF 23.4 BILLION IN SURVEY BY FINANCIAL NEWS WEBSITE PORTFOLIO.HU

BRIEF-Richter-Helm Biologics expands deal to support COVID-19 DNA vaccine trials

* RICHTER-HELM BIOLOGICS AND INOVIO TO EXPAND EXISTING DNA MANUFACTURING AGREEMENT TO SUPPORT LARGE-SCALE MANUFACTURING OF INOVIO'S INVESTIGATIONAL DNA VACCINE FOR COVID-19

BRIEF-Richter, Mycenax sign asset purchase agreement on biosimilar drug

Hungary's Richter says in statement on Budapest Stock Exchange web site:

BRIEF-Hungary's Richter Proposes Dividend Of 63 Forints Per Share

Richter Gedeon Vegyeszeti Gyar Nyrt says on Budapest Stock Exchange web site:

BRIEF-Hungary's Richter enters deal with Myovant Sciences on uterine fibroid medicine

* ENTERS INTO EXCLUSIVE AGREEMENT WITH MYOVANT SCIENCES TO SELL RELUGOLIX COMBINATION TABLET FOR UTERINE FIBROIDS AND ENDOMETRIOSIS IN CERTAIN TERRITORIES OUTSIDE THE U.S.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up